Payment overview · 2025
General Payments
$483.49
24 reported records · 12 companies
Healthcare provider profile · identity verified
Timothy Crater, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WINCHESTER, TN · NPI 1508845876
Verified facts
What the public records show
CMS Open Payments records show Timothy Crater, MD received $483.49 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.94 | 20.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.70 | 13.4% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.56 | 12.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.13 | 11.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $43.44 | 9.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.58 | 8.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.97 | 5.8% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $26.73 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.60 | 4.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.80 | 4.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.97 | 3.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.07 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $483.49 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.56 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $53.13 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.63 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.89 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.44 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $38.58 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.97 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.80 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 154 |
| Amlodipine Besylate | Amlodipine Besylate | 509 | 163 |
| Losartan Potassium | Losartan Potassium | 480 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 138 |
| Omeprazole | Omeprazole | 416 | 122 |
| Lisinopril | Lisinopril | 398 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 268 | 85 |
| Gabapentin | Gabapentin | 244 | 67 |
| Metformin Hcl | Metformin Hcl | 239 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 221 | 82 |
| Simvastatin | Simvastatin | 221 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 203 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 62 |
| Sertraline Hcl | Sertraline Hcl | 178 | 55 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 158 | 56 |
| Trazodone Hcl | Trazodone Hcl | 155 | 49 |
| Montelukast Sodium | Montelukast Sodium | 149 | 42 |
| Furosemide | Furosemide | 139 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 42 |
| Azithromycin | Azithromycin | 134 | 113 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 39 |
| Meloxicam | Meloxicam | 131 | 46 |
| Potassium Chloride | Potassium Chloride | 123 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 122 | 35 |
| Tramadol Hcl | Tramadol Hcl | 121 | 34 |
| Allopurinol | Allopurinol | 114 | 34 |
| Carvedilol | Carvedilol | 114 | 42 |
| Lorazepam | Lorazepam | 110 | 27 |
| Ozempic | Semaglutide | 110 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 33 |
| Methylprednisolone | Methylprednisolone | 104 | 86 |
| Atenolol | Atenolol | 100 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 37 |
| Eliquis | Apixaban | 96 | 20 |
| Alendronate Sodium | Alendronate Sodium | 91 | 25 |
| Ezetimibe | Ezetimibe | 84 | 24 |
| Alprazolam | Alprazolam | 83 | 14 |
| Clonazepam | Clonazepam | 80 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 18 |
| Bupropion Xl | Bupropion Hcl | 64 | 23 |
| Finasteride | Finasteride | 64 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 20 |
| Spironolactone | Spironolactone | 63 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 23 |
| Chlorthalidone | Chlorthalidone | 58 | 21 |
| Buspirone Hcl | Buspirone Hcl | 56 | 16 |
| Farxiga | Dapagliflozin Propanediol | 56 | 17 |
| Glipizide | Glipizide | 56 | 16 |
| Valsartan | Valsartan | 56 | 18 |
| Lovastatin | Lovastatin | 55 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 14 |
| Metformin Hcl Er | Metformin Hcl | 52 | 16 |
| Levofloxacin | Levofloxacin | 49 | 37 |
| Warfarin Sodium | Warfarin Sodium | 49 | suppressed |
| Xarelto | Rivaroxaban | 49 | 11 |
| Jardiance | Empagliflozin | 46 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 13 |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 16 |
| Levemir Flexpen | Insulin Detemir | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 12 |
| Azelastine Hcl | Azelastine Hcl | 37 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 25 |
| Famotidine | Famotidine | 37 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 11 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Mounjaro | Tirzepatide | 34 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 11 |
| Nifedipine Er | Nifedipine | 30 | 12 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 28 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 12 |
| Estradiol | Estradiol | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 14 |
| Ramipril | Ramipril | 21 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Verapamil Sr | Verapamil Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $483.49 · 24 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, IBSRELA, Kerendia, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error